Squarepoint Ops LLC increased its position in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) by 6.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 82,317 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,843 shares during the quarter. Squarepoint Ops LLC owned 0.25% of Collegium Pharmaceutical worth $945,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. lifted its stake in Collegium Pharmaceutical by 33.0% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 6,041 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 1,500 shares during the last quarter. Meeder Asset Management Inc. lifted its stake in Collegium Pharmaceutical by 1,299.5% in the third quarter. Meeder Asset Management Inc. now owns 8,495 shares of the specialty pharmaceutical company’s stock valued at $97,000 after buying an additional 7,888 shares during the last quarter. Nisa Investment Advisors LLC bought a new stake in Collegium Pharmaceutical in the third quarter valued at $98,000. Campbell & CO Investment Adviser LLC bought a new stake in Collegium Pharmaceutical in the third quarter valued at $116,000. Finally, Janney Montgomery Scott LLC bought a new stake in Collegium Pharmaceutical in the third quarter valued at $126,000. Hedge funds and other institutional investors own 91.10% of the company’s stock.

In related news, Director David Hirsch sold 25,000 shares of Collegium Pharmaceutical stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $19.33, for a total transaction of $483,250.00. Following the sale, the director now directly owns 17,117 shares in the company, valued at $330,871.61. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Joseph Ciaffoni sold 64,821 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $18.77, for a total transaction of $1,216,690.17. Following the sale, the chief executive officer now owns 242,276 shares in the company, valued at $4,547,520.52. The disclosure for this sale can be found here. 8.08% of the stock is owned by insiders.

COLL stock opened at $20.95 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.20 and a current ratio of 1.24. The stock has a market capitalization of $702.39 million, a price-to-earnings ratio of -17.61 and a beta of 0.83. Collegium Pharmaceutical Inc has a 1 year low of $10.01 and a 1 year high of $22.28. The stock’s fifty day moving average is $18.03 and its two-hundred day moving average is $13.19.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The company had revenue of $72.94 million for the quarter, compared to the consensus estimate of $74.32 million. During the same quarter in the prior year, the firm earned ($0.50) earnings per share. Collegium Pharmaceutical’s revenue for the quarter was up 3.9% compared to the same quarter last year. As a group, analysts predict that Collegium Pharmaceutical Inc will post -0.64 EPS for the current fiscal year.

A number of equities research analysts have issued reports on COLL shares. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Collegium Pharmaceutical in a research note on Friday. SunTrust Banks raised their target price on Collegium Pharmaceutical to $22.00 and gave the company a “buy” rating in a research note on Friday, November 8th. William Blair reiterated a “buy” rating on shares of Collegium Pharmaceutical in a research note on Tuesday, September 17th. ValuEngine upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, Jefferies Financial Group raised their target price on Collegium Pharmaceutical from $26.00 to $36.00 in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Story: What is a bull market?

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.